ProMIS Neurosciences Inc. Common Shares (ON) PMN
$3.31
-70.13%
at last close
Analyst Consensus
- Consensus Rating
- Buy (5 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $42.50
- Implied Upside
- +1184.0%
- Price Target Range
- $18.00 – $100.00
- Analysts (12 mo)
- 5
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-14 | GuggenheimYatin Suneja |
Maintains | Buy | $69 → $100 |
| 2026-07-29 | GuggenheimEddie Hickman |
Maintains | Buy | $35 → $69 |
| 2026-07-28 | Chardan CapitalKeay Nakae |
Maintains | Buy | $20 → $33 |
| 2026-07-27 | Chardan CapitalKeay Nakae |
Initiates coverage on | Buy | $20 |
| 2026-07-08 | Roth CapitalBoobalan Pachaiyappan |
Initiates coverage on | Buy | $19 |
| 2026-06-30 | Cantor FitzgeraldPete Stavropoulos |
Initiates coverage on | Overweight | — |
| 2026-06-24 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $18 |
| 2026-06-08 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $18 |
| 2026-02-06 | GuggenheimEddie Hickman |
Maintains | Buy | $125 → $35 |
| 2025-12-01 | HC Wainwright & Co.Raghuram Selvaraju |
Maintains | Buy | $4 → $18 |
| 2025-11-21 | HC Wainwright & Co.Raghuram Selvaraju |
Reiterates | Buy | $100 |
| 2025-11-18 | GuggenheimEddie Hickman |
Maintains | Buy | $150 → $125 |
| 2025-07-14 | HC Wainwright & Co.Raghuram Selvaraju |
Initiates coverage on | Buy | $4 |
| 2025-05-12 | Maxim GroupJason McCarthy |
Initiates coverage on | Buy | $3 |
| 2025-04-01 | GuggenheimEddie Hickman |
Reiterates | Buy | $6 |
| 2025-02-26 | GuggenheimEddie Hickman |
Reiterates | Buy | — |
| 2023-10-03 | BTIGThomas Shrader |
Initiates coverage on | Buy | $8 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $3.31
- Market Cap
- $99.36 million
- 52-Week Range
- $3.21 – $27.40
- Average Volume
- 89K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.
